Online citations, reference lists, and bibliographies.
← Back to Search

Pain And Beyond: Fatty Acid Amides And Fatty Acid Amide Hydrolase Inhibitors In Cardiovascular And Metabolic Diseases.

Sivaram Pillarisetti, C. W. Alexander, I. Khanna
Published 2009 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Fatty acid amide hydrolase (FAAH) is responsible for the hydrolysis of several important endogenous fatty acid amides (FAAs), including anandamide, oleoylethanolamide and palmitoylethanolamide. Because specific FAAs interact with cannabinoid and vanilloid receptors, they are often referred to as 'endocannabinoids' or 'endovanilloids'. Initial interest in this area, therefore, has focused on developing FAAH inhibitors to augment the actions of FAAs and reduce pain. However, recent literature has shown that these FAAs - through interactions with unique receptors (extracellular and intracellular) - can induce a diverse array of effects that include appetite suppression, modulation of lipid and glucose metabolism, vasodilation, cardiac function and inflammation. This review gives an overview of FAAs and diverse FAAH inhibitors and their potential therapeutic utility in pain and non-pain indications.
This paper references
10.2174/1381612023395655
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications.
T. Bisogno (2002)
10.1021/jm701631z
Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates.
M. Mor (2008)
10.1073/pnas.0806121105
Structure-guided inhibitor design for human FAAH by interspecies active site conversion
Mauro Mileni (2008)
10.1124/jpet.108.142224
Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3′-Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats
M. Scherma (2008)
10.1038/sj.bjp.0707145
Analgesic actions of N‐arachidonoyl‐serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors
S. Maione (2007)
10.1021/JM031140X
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
M. Mor (2004)
10.1146/ANNUREV.BIOCHEM.74.082803.133450
Structure and function of fatty acid amide hydrolase.
M. K. McKinney (2005)
10.1152/AJPHEART.00107.2005
Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase.
P. Pacher (2005)
10.1007/s00109-006-0139-0
The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites
D. P. Jensen (2006)
10.1016/S0006-8993(98)00969-X
Anandamide modulates sleep and memory in rats
E. Murillo-Rodríguez (1998)
10.1002/CHIN.199945334
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?
D. Lambert (1999)
10.1038/sj.bjp.0706510
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models
A. Jayamanne (2006)
10.1021/JM049614V
Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics.
D. Boger (2005)
10.1021/jm701210y
Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase.
F. Kimball (2008)
10.1021/JM050484F
Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
G. Muccioli (2006)
10.1053/GAST.2002.34242
Endocannabinoids as physiological regulators of colonic propulsion in mice.
L. Pinto (2002)
10.1054/PLEF.2001.0356
Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance.
T. Sugiura (2002)
10.1016/j.pain.2007.03.008
Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain
M. Suardíaz (2007)
10.1073/pnas.0901515106
Identification of intracellular carriers for the endocannabinoid anandamide
M. Kaczocha (2009)
10.1016/S0024-3205(98)00052-6
Distribution and characterization of anandamide amidohydrolase in mouse brain and liver.
K. Watanabe (1998)
10.1038/sj.bjp.0704732
‘Entourage’ effects of N‐acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide‐induced vanilloid receptor activation and upon anandamide metabolism
D. Smart (2002)
10.1016/j.febslet.2007.05.037
Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators
C. Tham (2007)
10.1038/sj.bjp.0706699
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms
L. Chang (2006)
10.1038/bjp.2008.324
‘Entourage’ effects of N‐palmitoylethanolamide and N‐oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors
W. Ho (2008)
10.1016/J.EJPHAR.2006.07.024
Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
V. Haller (2006)
10.1016/J.PHARMTHERA.2007.01.005
Biochemistry and pharmacology of endovanilloids.
K. Starowicz (2007)
10.1016/0024-3205(89)90278-6
Identification of fatty acid amides in human plasma.
E. S. Arafat (1989)
10.1006/EXER.1996.0265
Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues.
S. Matsuda (1997)
10.1021/JA062999H
The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases.
J. Alexander (2006)
10.1126/SCIENCE.1076535
Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling
M. Bracey (2002)
10.1111/j.1365-2982.2008.01246.x
GLP‐1 regulates gastroduodenal motility involving cholinergic pathways
J. Schirra (2009)
10.1016/S0009-3084(02)00152-4
Endocannabinoids and related fatty acid derivatives in pain modulation.
J. M. Walker (2002)
10.1126/SCIENCE.1470919
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
W. Devane (1992)
10.1074/jbc.M509721200
Anandamide Uptake Is Consistent with Rate-limited Diffusion and Is Regulated by the Degree of Its Hydrolysis by Fatty Acid Amide Hydrolase*
M. Kaczocha (2006)
10.1124/MOL.104.006353
The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide
J. Lo Verme (2005)
10.1073/pnas.161191698
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
B. Cravatt (2001)
10.1002/(SICI)1096-9861(19991206)415:1<80::AID-CNE6>3.0.CO;2-H
Immunocytochemical localization of cannabinoid CB1 receptor and fatty acid amide hydrolase in rat retina
S. Yazulla (1999)
10.1038/sj.bjp.0705467
Anandamide and vanilloid TRPV1 receptors
R. Ross (2003)
10.1038/bjp.2008.177
Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice
R. Capasso (2008)
10.1021/JM00020A011
Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl alpha-ketobenzoxazoles.
P. D. Edwards (1995)
10.1016/j.neuropharm.2007.08.011
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition
M. Scherma (2008)
10.1152/AJPHEART.00373.2007
Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase.
S. Bátkai (2007)
10.1021/BI060163L
Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids.
D. Leung (2006)
10.1038/sj.bjp.0704333
Mechanisms of anandamide‐induced vasorelaxation in rat isolated coronary arteries
R. White (2001)
10.1124/JPET.104.069401
Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity
A. Lichtman (2004)
10.1016/J.CMET.2006.02.004
Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents.
H. A. Overton (2006)
10.1046/J.1432-1033.2000.01316.X
Down-regulation of anandamide hydrolase in mouse uterus by sex hormones.
M. Maccarrone (2000)
10.1038/sj.bjp.0707682
The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high‐fat diet
V. Di Marzo (2008)
10.1016/J.CHEMBIOL.2007.05.014
Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology.
V. Di Marzo (2007)
10.1016/j.ejphar.2008.07.032
Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test.
S. Lisboa (2008)
10.1021/JM050977K
Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates.
G. Muccioli (2006)
10.1038/sj.bjp.0706348
Inhibitors of fatty acid amide hydrolase reduce carrageenan‐induced hind paw inflammation in pentobarbital‐treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors
S. Holt (2005)
10.1002/CBDV.200790157
Fatty Acid Amide Hydrolase: From Characterization to Therapeutics
G. Labar (2007)
10.1021/BI991876P
Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism.
M. Patricelli (1999)
10.1054/PLEF.2001.0345
Endocannabinoids and the gut.
L. Pinto (2002)
10.1038/sj.bjp.0706773
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms
Leon Chang (2006)
10.1021/JM058183T
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
D. Lambert (2005)
10.1016/j.neuropharm.2008.04.018
Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain
M. Jhaveri (2008)
10.1016/j.psyneuen.2007.02.003
Estrogen recruits the endocannabinoid system to modulate emotionality
M. Hill (2007)
10.1007/s00213-006-0589-7
Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat
S. Cross-Mellor (2006)
10.1007/s00213-007-0970-1
The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat
E. Rock (2007)
10.1016/j.neuropharm.2006.11.009
Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets
D. Zhang (2007)
10.1038/nature01921
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α
J. Fu (2003)
10.1007/s00109-008-0305-7
Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice
G. Aviello (2008)
10.1523/JNEUROSCI.3326-06.2006
Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain
M. Jhaveri (2006)
10.1016/j.drudis.2008.02.006
Biosynthesis, degradation and pharmacological importance of the fatty acid amides.
Emma K. Farrell (2008)
10.1038/SJ.BJP.0707478
Cannabinoid activation of PPARα; a novel neuroprotective mechanism
Y. Sun (2007)
10.1111/j.1365-2826.2008.01689.x
A Saturated N‐Acylethanolamine Other than N‐Palmitoyl Ethanolamine with Anti‐inflammatory Properties: a Neglected Story…
M. Dalle Carbonare (2008)
10.1126/SCIENCE.7770779
Chemical characterization of a family of brain lipids that induce sleep.
B. Cravatt (1995)
10.1038/sj.bjp.0703902
Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide
C. Lagneux (2001)
10.1021/BI701378G
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
K. Ahn (2007)
10.1016/S0083-6729(01)62002-8
Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides.
M. Patricelli (2001)
10.1016/j.pain.2004.01.022
Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia
A. Lichtman (2004)
10.1172/JCI28621
Fatty acid amide hydrolase deficiency limits early pregnancy events.
H. Wang (2006)
10.2337/db08-1237
GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell
L. Lauffer (2009)
10.1016/j.ejphar.2008.06.061
Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis.
P. Hasanein (2008)
10.1111/J.1527-3466.2007.00004.X
Oleamide: a fatty acid amide signaling molecule in the cardiovascular system?
C. Hiley (2007)
10.2337/db06-0812
Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
M. Blüher (2006)
10.1124/jpet.106.105221
Pharmacological Characterization of Hydrolysis-Resistant Analogs of Oleoylethanolamide with Potent Anorexiant Properties
G. Astarita (2006)
10.1016/J.EJPHAR.2007.09.034
Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart.
A. R. Hajrasouliha (2008)
10.1016/S0008-6363(02)00268-7
Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts.
M. Joyeux (2002)
10.1038/bjp.2008.335
Inhibition of fatty acid amide hydrolase produces PPAR‐α‐mediated analgesia in a rat model of inflammatory pain
D. R. Sagar (2008)
10.1038/sj.bjp.0707529
GPR119, a novel G protein‐coupled receptor target for the treatment of type 2 diabetes and obesity
H. A. Overton (2008)
10.1038/sj.bjp.0705725
The complexities of the cardiovascular actions of cannabinoids
M. Randall (2004)
10.1073/PNAS.97.10.5044
Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide.
D. Boger (2000)
10.1073/PNAS.96.21.12198
Pain modulation by release of the endogenous cannabinoid anandamide.
J. M. Walker (1999)
10.1038/sj.bjp.0704900
Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo‐oxygenase systems
B. Costa (2002)
10.1016/S0006-8993(98)01031-2
Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity
N. Strangman (1998)
10.1213/ane.0b013e31818c7cbd
Biochemical and Biological Properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a Mechanism-Based Inhibitor of Fatty Acid Amide Hydrolase
Mark J. Karbarz (2009)
10.1210/JC.2005-2679
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia.
I. Matias (2006)
10.1021/jm800311k
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
M. Seierstad (2008)
10.2174/138955706776073466
New insights into endocannabinoid degradation and its therapeutic potential.
M. Bari (2006)
10.1111/j.1365-2826.2008.01686.x
Gastrointestinal Regulation of Food Intake: General Aspects and Focus on Anandamide and Oleoylethanolamide
R. Capasso (2008)
10.1055/s-0028-1087169
The fatty acid amide hydrolase (FAAH) Pro129Thr polymorphism is not associated with severe obesity in Greek subjects.
D. Papazoglou (2008)
10.2174/0929867023370707
The palmitoylethanolamide family: a new class of anti-inflammatory agents?
D. Lambert (2002)
10.1038/sj.ijo.0802954
Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH)
J. Sipe (2005)
10.1074/jbc.M507429200
Endogenous Unsaturated C18 N-Acylethanolamines Are Vanilloid Receptor (TRPV1) Agonists*
P. Movahed (2005)
10.1073/PNAS.0509591102
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.
G. Gobbi (2005)
10.1016/j.neuropharm.2007.07.005
Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors
F. Moreira (2008)
10.1016/j.tips.2008.12.004
The enigmatic pharmacology of GPR55.
R. Ross (2009)
10.2174/138161206777947425
Cannabinoids, immune system and cytokine network.
P. Massi (2006)
10.1073/PNAS.92.8.3376
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.
L. Facci (1995)
10.1002/0470846305.CH14
The Amino Acid Conjugations
G. Steventon (2002)
10.1016/S0014-2999(97)01007-8
Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells.
E. Berdyshev (1997)
10.1113/jphysiol.2004.081844
Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short‐term food intake in mice via capsaicin receptor TRPV1
Xiangbin Wang (2005)
10.1016/J.BMCL.2004.12.085
Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity.
D. Leung (2005)
Endocannabinoids and vascular function.
C. Hillard (2000)
10.1021/JM0611509
Potent and Selective α-Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase
F. Romero (2007)
10.1074/jbc.M607809200
Food Intake Regulates Oleoylethanolamide Formation and Degradation in the Proximal Small Intestine*
Jin Fu (2007)
10.1074/jbc.M303922200
Evidence for Distinct Roles in Catalysis for Residues of the Serine-Serine-Lysine Catalytic Triad of Fatty Acid Amide Hydrolase*
M. K. McKinney (2003)
10.1074/jbc.M404087200
Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor α (PPAR-α)*
M. Guzmán (2004)
10.1038/sj.bjp.0704466
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat
S. Conti (2002)
10.1016/j.physbeh.2009.02.014
The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew)
L. Parker (2009)
10.1016/0091-3057(93)90230-Q
Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents
J. Crawley (1993)
10.1098/rstb.2006.1856
Gastrointestinal hormones regulating appetite
O. Chaudhri (2006)
10.1021/jm800136b
Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase.
Joie Garfunkle (2008)
10.1038/sj.bjp.0707424
Role and regulation of acylethanolamides in energy balance: focus on adipocytes and β‐cells
I. Matias (2007)
10.1006/BBRC.1998.8874
Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.
T. Bisogno (1998)
10.1124/jpet.108.150136
Endocannabinoid Modulation of Scratching Response in an Acute Allergenic Model: A New Prospective Neural Therapeutic Target for Pruritus
J. Schlosburg (2009)
Hydrolysis of anandamide and eicosapentaenoic acid ethanolamide in mouse splenocytes.
M. Bobrov (2000)
10.1038/sj.bjp.0707423
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
S. O’Sullivan (2007)
10.1096/fj.05-4943fje
Up‐regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation
G. D'argenio (2006)
10.1038/sj.emboj.7600784
Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels
M. van der Stelt (2005)
10.1124/jpet.106.101287
Pharmacological Evaluation of Cannabinoid Receptor Ligands in a Mouse Model of Anxiety: Further Evidence for an Anxiolytic Role for Endogenous Cannabinoid Signaling
S. Patel (2006)
10.1038/nrd2553
Targeting the endocannabinoid system: to enhance or reduce?
V. Marzo (2008)
10.1016/j.bmcl.2008.07.081
Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase.
J. Keith (2008)
10.1073/PNAS.0507470102
Identification of a high-affinity binding site involved in the transport of endocannabinoids.
S. Moore (2005)
10.1111/J.1527-3458.2006.00021.X
Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597).
D. Piomelli (2006)
10.1208/s12248-008-9075-y
Targeting Fatty Acid Amide Hydrolase (FAAH) to Treat Pain and Inflammation
J. Schlosburg (2008)
10.1016/J.LFS.2005.05.007
Anandamide transport: a critical review.
S. Glaser (2005)
10.1016/S0005-2760(97)00078-7
Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine.
K. Katayama (1997)
10.1124/jpet.107.119941
The Fatty Acid Amide Hydrolase Inhibitor URB597 (Cyclohexylcarbamic Acid 3′-Carbamoylbiphenyl-3-yl Ester) Reduces Neuropathic Pain after Oral Administration in Mice
R. Russo (2007)
10.1016/J.PROSTAGLANDINS.2004.09.017
Targeted lipidomics: fatty acid amides and pain modulation.
J. M. Walker (2005)
10.1016/J.BMC.2004.07.026
The anandamide membrane transporter. Structure-activity relationships of anandamide and oleoylethanolamine analogs with phenyl rings in the polar head group region.
V. Di Marzo (2004)
10.1016/j.bmcl.2008.05.081
3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors.
A. Urbach (2008)
10.1021/jm801042a
Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors.
X. Wang (2009)
10.1124/jpet.107.123265
Acute Intracerebroventricular Administration of Palmitoylethanolamide, an Endogenous Peroxisome Proliferator-Activated Receptor-α Agonist, Modulates Carrageenan-Induced Paw Edema in Mice
G. D’Agostino (2007)
10.1172/JCI19465
The endogenous cannabinoid system protects against colonic inflammation.
F. Massa (2004)
10.1016/S0009-3084(00)00194-8
Endocannabinoids as cardiovascular modulators.
G. Kunos (2000)
10.1172/JCI30227
Gastrointestinal regulation of food intake.
D. Cummings (2007)
10.1016/j.bmcl.2008.01.091
Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH).
Amy Timmons (2008)
10.1016/S0006-2952(96)00830-1
Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase.
D. Deutsch (1997)
10.1016/S0024-3205(98)00324-5
Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice.
E. Berdyshev (1998)
10.1074/JBC.270.11.6030
Anandamide Amidohydrolase Activity in Rat Brain Microsomes
F. Desarnaud (1995)
10.1016/j.pain.2008.06.003
The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors
B. Costa (2008)
10.1172/JCI119677
Production and physiological actions of anandamide in the vasculature of the rat kidney.
D. Deutsch (1997)
10.1016/j.neuropharm.2005.02.013
Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats
J. Fu (2005)
10.2174/156802608783498005
Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
S. Vandevoorde (2008)
10.1038/nbt826
Discovering potent and selective reversible inhibitors of enzymes in complex proteomes
D. Leung (2003)
10.1074/JBC.M008555200
The Activity of Anandamide at Vanilloid VR1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism*
L. De Petrocellis (2001)
10.1073/PNAS.96.10.5802
Structural determinants for recognition and translocation by the anandamide transporter.
D. Piomelli (1999)
10.1161/01.CIR.0000143230.23252.D2
Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension
S. Bátkai (2004)
10.1098/rspb.1998.0543
A new perspective on cannabinoid signalling: complimentary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain.
M. Egertová (1998)
10.1016/J.TVJL.2005.10.003
Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals.
G. Re (2007)
10.1038/nature05506
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models
A. Kreitzer (2007)
10.1016/S0163-7258(02)00258-9
Cardiovascular effects of cannabinoids.
M. Randall (2002)
10.1007/s00109-008-0359-6
Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors
M. Storr (2008)
10.1016/j.biopsych.2006.12.001
Antidepressant-like Activity of the Fatty Acid Amide Hydrolase Inhibitor URB597 in a Rat Model of Chronic Mild Stress
M. Bortolato (2007)
10.1074/jbc.M606646200
A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals*
B. Q. Wei (2006)
10.1007/s001090050287
Cardiovascular actions of cannabinoids and their generation during shock
J. Wagner (1998)
10.1016/J.EJMECH.2007.02.023
Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation.
G. Ortar (2008)
10.1016/J.BMCL.2007.04.009
Novel inhibitors of fatty acid amide hydrolase.
S. Sit (2007)
10.1016/j.expneurol.2007.07.021
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptors
M. G. Morgese (2007)
10.1021/BI0608008
A FAAH-regulated class of N-acyl taurines that activates TRP ion channels.
A. Saghatelian (2006)



This paper is referenced by
10.1016/j.bmcl.2010.06.149
Synthesis and antituberculosis activity of new fatty acid amides.
C. R. M. D'Oca (2010)
10.1021/jm301492y
Radiosynthesis and Evaluation of [11C-Carbonyl]-Labeled Carbamates as Fatty Acid Amide Hydrolase Radiotracers for Positron Emission Tomography
A. Wilson (2013)
Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options.
M. Bennetzen (2011)
10.15407/UBJ89.05.062
Modulation of LPS-induced ROS production and NF-?B nuclear translocation by N-stearoylethanolamine in macrophages
A. G. Berdyshev (2017)
10.1016/j.nucmedbio.2010.08.001
[11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography.
A. Wilson (2011)
10.3390/ijms20184326
Multi-Staged Regulation of Lipid Signaling Mediators during Myogenesis by COX-1/2 Pathways
Chenglin Mo (2019)
The health effects of sea buckthorn berries and oil
P. Larmo (2011)
10.1111/bph.12030
N‐acyl amines of docosahexaenoic acid and other n–3 polyunsatured fatty acids – from fishy endocannabinoids to potential leads
J. Meijerink (2013)
10.1007/s11307-014-0789-1
Synthesis and Preclinical Evaluation of [18F]FCHC for Neuroimaging of Fatty Acid Amide Hydrolase
T. Shoup (2014)
10.1016/j.bmcl.2015.12.103
New approaches to treating pain.
A. Wolkerstorfer (2016)
10.3109/14756366.2013.837900
(S)-1-(Pent-4′-enoyl)-4-(hydroxymethyl)-azetidin-2-one derivatives as inhibitors of human fatty acid amide hydrolase (hFAAH): synthesis, biological evaluation and molecular modelling
J. Caruano (2014)
10.1016/j.ejmech.2010.04.040
Chemistry around imidazopyrazine and ibuprofen: discovery of novel fatty acid amide hydrolase (FAAH) inhibitors.
Frédéric De Wael (2010)
10.1371/journal.pone.0016957
The Human Serum Metabolome
N. Psychogios (2011)
ANANDAMIDE , OLEAMIDE AND OTHER SIMPLE FATTY AMIDES STRUCTURE , OCCURRENCE
(2014)
10.1016/J.APSB.2011.04.003
Pharmacophore modeling and virtual screening for the discovery of new fatty acid amide hydrolase inhibitors
Dong-sheng Zhao (2011)
10.1111/j.1365-2125.2012.04175.x
Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol?
Carina Jarzimski (2012)
10.1177/1049909119850807
The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review
M. Davis (2019)
10.1016/j.bbalip.2012.07.021
Rat and human fatty acid amide hydrolases: overt similarities and hidden differences.
A. Di Venere (2012)
10.1371/journal.pone.0160505
New Biochemical Insights into the Mechanisms of Pulmonary Arterial Hypertension in Humans
R. Bujak (2016)
10.1517/13543784.2015.1020109
Investigational drugs under development for the treatment of PTSD
B. Ragen (2015)
10.1002/cbic.200900621
Crystal Structure of the Human Monoacylglycerol Lipase, a Key Actor in Endocannabinoid Signaling
G. Labar (2010)
10.1183/13993003.00782-2017
Targeting fatty acid amide hydrolase as a therapeutic strategy for antitussive therapy
M. Wortley (2017)
10.1002/oby.20498
Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study
J. Abdulnour (2014)
10.1016/j.bbalip.2011.07.008
Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract.
K. Verhoeckx (2011)
Inhibiteurs de l'hydrolase d'amides d'acides gras
Brian C. Austad (2011)
10.1016/j.bmcl.2011.12.032
Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.
S. Roughley (2012)
10.1007/s00044-017-1859-0
Phenacyl group containing amide derivative of dehydroabietylamine exhibiting enhanced cytotoxic activity against PLC and MCF7 cancer cell lines
Muhammad Ayaz Mustufa (2017)
Semantic Scholar Logo Some data provided by SemanticScholar